Stock Market Reviews

FTRE (Fortrea Holdings Inc.) News

Get the latest news, insights, and market updates on FTRE (Fortrea Holdings Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• What Catalysts Are Shifting the Story for Fortrea Holdings?
  Fortrea Holdings has seen its consensus analyst price target raised from $9.53 to $11.21. This signals a notable shift in market sentiment. This adjustment reflects renewed confidence among analysts, fueled by operational resilience and an improved business outlook despite ongoing leadership changes. Read on to discover how investors can track these evolving perspectives and stay informed about future shifts in Fortrea Holdings’ narrative. Stay updated as the Fair Value for Fortrea Holdings...
  Nov 17, 2025 - $FTRE
• Fortrea Appoints Agnieszka Gallagher as General Counsel
  DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company’s legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea’s leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period.
  Nov 17, 2025 - $FTRE
• 1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 11.6% return has trailed the S&P 500 by 4.7 percentage points.
  Nov 14, 2025 - $FTRE
• Fortrea Holdings (FTRE): Evaluating Valuation After Q3 Earnings Beat and Raised 2025 Revenue Guidance
  Fortrea Holdings (FTRE) just released its third quarter earnings, showing improved sales and a smaller net loss compared to last year. The company also raised its full-year 2025 revenue outlook, catching investors’ attention. See our latest analysis for Fortrea Holdings. After a challenging start to the year, Fortrea’s momentum has been shifting. While the year-to-date share price return sits at -45.2%, shares have rebounded with a 27.1% gain over the past three months. The recent bump...
  Nov 14, 2025 - $FTRE
• Q3 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks
  The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Fortrea (NASDAQ:FTRE) and the rest of the drug development inputs & services stocks fared in Q3.
  Nov 12, 2025 - $FTRE
• 5 Insightful Analyst Questions From Fortrea’s Q3 Earnings Call
  Fortrea’s third quarter results were met with a significant positive response from the market, as robust demand across its clinical pharmacology and clinical development businesses drove revenue growth. Management highlighted that win rates with biotech clients doubled compared to the prior quarter, and strong RFP volumes led to new business wins in both new and repeat clients. CEO Anshul Thakral credited operational improvements, noting, “Our win rates improved significantly, reaching the highe
  Nov 12, 2025 - $FTRE
• Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer
  Firm to target small to medium-sized biotech and pharma companies Drew Reina, CRO at Velocity Clinical Research Drew Reina, CRO at Velocity Clinical Research DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where
  Nov 12, 2025 - $FTRE
• Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025 - $FTRE
• Fortrea Holdings (FTRE) Is Up 7.6% After Raising 2025 Revenue Outlook on Strong Q3 Results - Has the Bull Case Changed?
  Fortrea Holdings reported results for the third quarter of 2025, exceeding revenue expectations with US$701.3 million in sales and revising full-year revenue guidance upward to a range of US$2.7 billion to US$2.75 billion. This announcement highlights strong demand and improved client win rates, alongside continued progress on technology and cost-saving initiatives in the competitive clinical research industry. We’ll consider how the raised revenue guidance and robust backlog enhance Fortrea...
  Nov 8, 2025 - $FTRE
• FTRE Q3 Deep Dive: Revenue Outpaces Estimates, Margin Expansion Remains a Focus
  Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 22.8% below analysts’ consensus estimates.
  Nov 6, 2025 - $FTRE